- Sharp, a contract packaging, clinical supply services and small-scale sterile manufacturing company, is expanding its Macungie, PA site.
- The site will double in size, adding 75-100 colleagues to its team once the GMP infrastructure is in place.
Sharp, a contract packaging, clinical supply services and small-scale sterile manufacturing company, has announced an expansion of its Macungie, PA site in North America. The expansion is aimed at increasing the company’s production capacity for sterile injectables secondary packaging.
The expansion will provide increased capacity for a variety of secondary packaging activities. These include Vial Labeling, Pre-Filled Syringe (PFS) assembly and labeling, Autoinjector/Pen assembly & labeling and Injectables Kitting and Cartoning. These services cater to the needs of pharmaceutical and biotech companies.
The expansion adds a significant 157,500 sq. ft. of open space, creating a 315,000-square-foot facility. This brings Sharp’s total global footprint to an impressive more than 1.7 million square feet.
Jeff Benedict, Chief Commercial Officer at Sharp, commented on the expansion, stating, “Demand for sterile injectable medicines has skyrocketed over the last few years due to increased investment in the biologics industry across all therapeutic categories, rare and orphan disease therapies, and blockbuster GLP-1 agonists”.
Kevin Orfan, CEO of Sharp, added, “With this expansion, the Macungie site will double in size allowing Sharp to offer additional capacity and capabilities for our biopharma clients for complex biologics and small-molecule injectable medicines”.
The plans for the site include the construction and fit-out of new packaging suites, ambient warehouse space, cold storage rooms as well as equipment and technology to support assembly, labelling and packaging of injectables. Once the GMP infrastructure is in place, Sharp anticipates adding 75-100 colleagues to its team.
Overview of outsourcing trends 
